The phase III ICE study: Adjudiscloseant Ibandronate with or without capecitabine in elderly patients with moderate or high risk early breast cancerGunter von Minckwitz, Toralf Reimer, Jochem Potenberg, Bettina Conrad, Heiko Graf, Holger Eidtmann, Marianne Just, Stephan Paepke, Elmar Stickeler, Georg Heinrich, Michael Untch, Volker Möbus, Christoph Thomssen, Christian Jackisch, Jens Huober, Sibylle Loibl, Valentina Nekljudova, Ulrike Nitz for the GBG / AGO-B / NOGGO / WSG study groups within the BIG framework

Gunter von Minckwitz

Dra. María del Rosario VidalJefa del Servicio de Oncología Clínica del Hospital de Morón

Estudio ICE Fase III: Ibandronato Adyuvante con o sin Capecitabina en Pacientes ancianas con cáncer de mama temprano con riesgo moderado o alto (GBG32, BIG 4-04)Gunter von Minckwitz, Toralf Reimer, Jochem Potenberg, Bettina Conrad, Heiko Graf, Holger Eidtmann, Marianne Just, Stephan Paepke, Elmar Stickeler, Georg Heinrich, Michael Untch, Volker Möbus, Christoph Thomssen, Christian Jackisch, Jens Huober, Sibylle Loibl, Valentina Nekljudova, Ulrike Nitz for the GBG / AGO-B / NOGGO / WSG study groups within the BIG framework